Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proof‐of‐concept study

• Published in: ESC Heart Failure Vol. 7; no. 6; pp. 4267 - 4276
• Main Authors: Lim, Shir Lynn, Gandhi, Mihir, Woo, Kai Lee, Chua, Horng Ruey, Lim, Yoke Ching, Sim, David K.L., Lee, Sheldon S.G., Teoh, Yee Leong, Richards, Arthur Mark, Lam, Carolyn S.P.
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.12.2020; John Wiley and Sons Inc; Wiley
• Subjects: Bioavailability; Biomarkers; Cardiorenal syndrome; Clinical outcomes; Drug dosages; Ejection fraction; Endothelial function; Enzymes; Exercise capacity; Heart failure; Hydralazine; ISDN; Isosorbide dinitrate; Mortality; Nitrates; Original; Original s; Pulmonary arteries; Ultrasonic imaging; Singapore; Cardiorenal syndrome; Isosorbide dinitrate; Endothelial function; Exercise capacity; Hydralazine

Aims Cardiorenal syndrome (CRS) is a common problem of great morbidity and mortality. Hydralazine–isosorbide dinitrate (H‐ISDN) may be used in renal failure and may improve exercise capacity in heart failure (HF). Our proof‐of‐concept study aimed to evaluate early evidence of efficacy, safety, and f...